GlassScriptPhysician profile
Stephen M Lipkin
NPI 1962475707
$11,726.85
in general payments reported to CMS, 2019-2025
50 companies · $2,858 in 2025
The $2,858 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,308 · 2020: $823 · 2021: $1,871 · 2022: $712 · 2023: $1,087 · 2024: $2,067 · 2025: $2,858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,913 · Consulting Fee: $98.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,913.23 |
| Consulting Fee | $98.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,570.56 | 2019-2025 | |
| Janssen Biotech, INC. | $895.15 | 2019-2025 | Stelara, Tremfya, Simponi |
| Alexion Pharmaceuticals, INC. | $711.18 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $636.40 | 2019-2025 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $532.49 | 2024-2025 | Rezdiffra |
| Daiichi Sankyo INC. | $390.29 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $378.70 | 2024-2025 | |
| Novo Nordisk INC | $366.38 | 2024-2025 | Wegovy, Ozempic |
| Ardelyx, INC. | $352.39 | 2023-2025 | Ibsrela |
| Janssen Scientific Affairs, LLC | $343.83 | 2019-2022 | |
| Gilead Sciences, INC. | $338.46 | 2020-2023 | Vemlidy |
| Shire North American Group INC | $285.92 | 2019 | |
| Phathom Pharmaceuticals, INC. | $280.85 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $262.24 | 2024-2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $261.37 | 2023-2024 | Zeposia |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Lipkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.